Can This Next-Gen Obesity Drug Save Novo Nordisk?
2026-03-07 10:50:00 ET
Things are going from bad to worse for Novo Nordisk (NYSE: NVO) . The Denmark-based drugmaker had already seen its blockbuster weight loss medicine, Wegovy, lose ground to Eli Lilly 's (NYSE: LLY) Zepbound in this fast-growing market. But Novo Nordisk just released data from a clinical trial for its newer obesity drug, CagriSema, in which it was pitted against Zepbound. The result: Zepbound came out on top, suggesting that even Novo Nordisk's next launch in this niche won't allow it to keep pace with its rival.
Is there any hope left for the pharmaceutical leader? Novo Nordisk quietly announced results from a phase 2 study of another candidate that investors should consider.
Image source: Getty Images.
NASDAQ: LLY
LLY Trading
0.45% G/L:
$1005.65 Last:
627,424 Volume:
$1006 Open:
